Supplementary Table 3. Prior migraine prophylactic medication category and discontinuation reasons (randomised analysis set)

| Medication category* | Erenumab 140 mg | Erenumab 70 mg | Placebo N=338 | All patients N=900 |
|----------------------|----------------|----------------|---------------|-------------------|
|                      | n (%)          | n (%)          | n (%)         | n (%)             |
| Any medication category | 119 (53.1)    | 181 (53.6)    | 179 (53.0)    | 479 (53.2)        |
| Treatment failure     | 77 (34.4)     | 106 (31.4)    | 106 (31.4)    | 289 (32.1)        |
| Lack of efficacy      | 57 (25.4)     | 85 (25.1)     | 70 (20.7)     | 212 (23.6)        |
| Lack of tolerability  | 29 (12.9)     | 33 (9.8)      | 43 (12.7)     | 105 (11.7)        |
| Medication no longer required | 53 (23.7) | 83 (24.6) | 77 (22.8) | 213 (23.7) |
| Other                | 29 (12.9)     | 44 (13.0)     | 48 (14.2)     | 121 (13.4)        |
| Divalproex sodium, sodium valproate | 16 (7.1)    | 26 (7.7)      | 26 (7.7)      | 68 (7.6)          |
| Treatment failure     | 11 (4.9)      | 10 (3.0)      | 8 (2.4)       | 29 (3.2)          |
| Lack of efficacy      | 8 (3.6)       | 6 (1.8)       | 5 (1.5)       | 19 (2.1)          |
| Lack of tolerability  | 3 (1.3)       | 4 (1.2)       | 3 (0.9)       | 10 (1.1)          |
| Medication no longer required | 2 (0.9) | 14 (4.1)       | 8 (2.4)       | 24 (2.7)          |
| Other                | 3 (1.3)       | 4 (1.2)       | 12 (3.6)      | 19 (2.1)          |
| Beta-blockers         | 64 (28.6)     | 91 (26.9)     | 85 (25.1)     | 240 (26.7)        |
| Treatment failure     | 28 (12.5)     | 37 (10.9)     | 33 (9.8)      | 98 (10.9)         |
| Lack of efficacy      | 23 (10.3)     | 36 (10.7)     | 26 (7.7)      | 85 (9.4)          |
| Lack of tolerability  | 5 (2.2)       | 1 (0.3)       | 7 (2.1)       | 13 (1.4)          |
| Medication no longer required | 29 (12.9) | 42 (12.4)       | 40 (11.8)       | 111 (12.3) |
| Category                          | Group 1 | Group 2 | Group 3 | Group 4 |
|----------------------------------|---------|---------|---------|---------|
|                                  | 7 (3.1) | 13 (3.8) | 12 (3.6) | 32 (3.6) |
| **Topiramate**                   | 43 (19.2) | 81 (24.0) | 72 (21.3) | 196 (21.8) |
| Treatment failure                | 24 (10.7) | 28 (8.3) | 33 (9.8) | 85 (9.4) |
| Lack of efficacy                 | 5 (2.2) | 13 (3.8) | 12 (3.6) | 30 (3.3) |
| Lack of tolerability             | 19 (8.5) | 15 (4.4) | 21 (6.2) | 55 (6.1) |
| Medication no longer required    | 11 (4.9) | 40 (11.8) | 28 (8.3) | 79 (8.8) |
| Other                            | 8 (3.6) | 16 (4.7) | 14 (4.1) | 38 (4.2) |
| **Lisinopril, candesartan**      | 1 (0.4) | 1 (0.3) | 1 (0.3) | 3 (0.3) |
| Treatment failure                | 1 (0.4) | 1 (0.3) | 0 | 2 (0.2) |
| Lack of efficacy                 | 0 | 1 (0.3) | 0 | 1 (0.1) |
| Lack of tolerability             | 1 (0.4) | 0 | 0 | 1 (0.1) |
| Other                            | 0 | 0 | 1 (0.3) | 1 (0.1) |
| **Serotonin-norepinephrine reuptake inhibitors** | 5 (2.2) | 10 (3.0) | 4 (1.2) | 19 (2.1) |
| Treatment failure                | 4 (1.8) | 3 (0.9) | 0 | 7 (0.8) |
| Lack of efficacy                 | 2 (0.9) | 1 (0.3) | 0 | 3 (0.3) |
| Lack of tolerability             | 2 (0.9) | 2 (0.6) | 0 | 4 (0.4) |
| Medication no longer required    | 1 (0.4) | 5 (1.5) | 4 (1.2) | 10 (1.1) |
| Other                            | 0 | 3 (0.9) | 0 | 3 (0.3) |
| **Flunarizine, verapamil**       | 46 (20.5) | 70 (20.7) | 66 (19.5) | 182 (20.2) |
| Treatment failure                | 15 (6.7) | 30 (8.9) | 21 (6.2) | 66 (7.3) |
| Lack of efficacy                 | 11 (4.9) | 21 (6.2) | 9 (2.7) | 41 (4.6) |
| Lack of tolerability             | 4 (1.8) | 9 (2.7) | 12 (3.6) | 25 (2.8) |
| Category                        | 1       | 2       | 3       | 4       |
|--------------------------------|---------|---------|---------|---------|
| Medication no longer required  | 20 (8.9)| 27 (8.0)| 31 (9.2)| 78 (8.7)|
| Other                          | 12 (5.4)| 14 (4.1)| 15 (4.4)| 41 (4.6)|
| **Tricyclic antidepressants**  |         |         |         |         |
| Treatment failure              | 67 (29.9)| 96 (28.4)| 72 (21.3)| 235 (26.1)|
| Lack of efficacy               | 40 (17.9)| 52 (15.4)| 50 (14.8)| 142 (15.8)|
| Lack of tolerability           | 30 (13.4)| 41 (12.1)| 32 (9.5)| 103 (11.4)|
| Other                          | 10 (4.5)| 11 (3.3)| 18 (5.3)| 39 (4.3)|
| Medication no longer required  | 18 (8.0)| 30 (8.9)| 19 (5.6)| 67 (7.4)|
| Other                          | 9 (4.0)| 16 (4.7)| 4 (1.2)| 29 (3.2)|
| **Other migraine prophylactic**|         |         |         |         |
| Medications                    |         |         |         |         |
| Treatment failure              | 24 (10.7)| 32 (9.5)| 36 (10.7)| 92 (10.2)|
| Lack of efficacy               | 5 (2.2)| 3 (0.9)| 11 (3.3)| 19 (2.1)|
| Lack of tolerability           | 3 (1.3)| 2 (0.6)| 8 (2.4)| 13 (1.4)|
| Other                          | 2 (0.9)| 1 (0.3)| 3 (0.9)| 6 (0.7)|
| Medication no longer required  | 14 (6.3)| 21 (6.2)| 21 (6.2)| 56 (6.2)|
| Other                          | 5 (2.2)| 8 (2.4)| 6 (1.8)| 19 (2.1)|

*Categories are not mutually exclusive and patients may contribute to >1 category.*